Table 5 Summary of the cost and health outcomes results
Sintilimab plus chemotherapy | Placebo plus chemotherapy | |
|---|---|---|
QALYs | 1.52 | 0.92 |
PF QALYs | 1.00 | 0.47 |
PP QALYs | 0.52 | 0.45 |
Total costs | ¥413,273.16 | ¥280,695.23 |
Drug costs | ¥368,860.32 | ¥200,158.20 |
Administration costs | ¥2753.56 | ¥13,762.61 |
Disease | ¥18,230.80 | ¥10,808.29 |
management and | ||
monitoring costs | ||
AE costs | ¥4973.97 | ¥4894.61 |
Subsequent | ¥18,454.51 | ¥51,071.52 |
therapy costs | ||
Average cost-effectiveness ratios (ACER) | ¥271,890.23/QALY, | ¥305,103.51/QALY |
Incremental costs | ¥132,577.93 | |
Incremental QALYs | 0.60 | |
ICER | ¥220,963.22/QALY | |